Of note, one of the most frequently investigated human-melanoma-associated antigens, chondroitin sulfate proteoglycan (CSPG)4, is expressed by most OMM and appears to play a relevant role in clinical outcome, as discussed below (8, 10, 18–20). The gene discussed is CSPG4; the disease is melanoma.